Clinical and Immunological Evaluation of T cell- and Antibody-Inducing Viral Vector Vaccines against Blood-Stage Malar
针对血期颧骨的 T 细胞和抗体诱导病毒载体疫苗的临床和免疫学评价
基本信息
- 批准号:G1000527/1
- 负责人:
- 金额:$ 140.75万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Fellowship
- 财政年份:2010
- 资助国家:英国
- 起止时间:2010 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Malaria remains a huge public health problem in the developing world. The development of an effective vaccine remains an important but elusive goal. Malaria is caused by a parasite that first infects the liver before moving into the blood where it causes disease. A few vaccines have been developed recently that can kill some parasites in the liver, however, there is still no vaccine that can kill parasites in the blood.This research will test a new vaccine technology against the parasites in the blood. These vaccines, developed by scientists at the Jenner Institute, Oxford University, use viruses that are genetically engineered to look like malaria parasites. The work will test the safety and effectiveness of these vaccines in volunteers in clinical trials in Oxford, and importantly also study the immune responses produced by them. Scientists can then attempt to figure out which immune responses are killing the parasites. This research will also assess how malaria infection can interfere with immune responses in humans in both the UK and Africa. It is extremely important to understand these interactions between malaria parasites and the human immune system, because we can use this information to help design better vaccines in the future.
在发展中国家,疟疾仍然是一个巨大的公共卫生问题。开发有效的疫苗仍然是一个重要但难以实现的目标。疟疾是由一种寄生虫引起的,这种寄生虫首先感染肝脏,然后进入血液,在血液中致病。最近已经开发出一些疫苗可以杀死肝脏中的一些寄生虫,但仍然没有疫苗可以杀死血液中的寄生虫。这项研究将测试一种针对血液中寄生虫的新疫苗技术。这些疫苗由牛津大学詹纳研究所的科学家开发,使用的病毒经过基因工程,看起来像疟疾寄生虫。这项工作将在牛津的临床试验中在志愿者身上测试这些疫苗的安全性和有效性,重要的是还将研究它们产生的免疫反应。然后,科学家可以尝试找出是哪种免疫反应杀死了寄生虫。这项研究还将评估疟疾感染如何干扰英国和非洲人类的免疫反应。了解疟疾寄生虫和人类免疫系统之间的这些相互作用是极其重要的,因为我们可以利用这些信息来帮助未来设计更好的疫苗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Simon Draper其他文献
Analysis of peripheral blood B and Tfh cells as predictors of antibody responses in individuals receiving candidate blood-stage malaria vaccines in a Phase Ia clinical trial
- DOI:
10.1186/1475-2875-13-s1-p28 - 发表时间:
2014-09-22 - 期刊:
- 影响因子:3.000
- 作者:
Sean Elias;Kathryn Milne;Cecilia Chui;Susanne Hodgson;Persephone Borrow;Simon Draper - 通讯作者:
Simon Draper
Towards a multi-antigen multi-stage malaria vaccine
- DOI:
10.1186/1475-2875-13-s1-o31 - 发表时间:
2014-09-22 - 期刊:
- 影响因子:3.000
- 作者:
Adrian VS Hill;Sumi Biswas;Simon Draper;Thomas Rampling;Arturo Reyes-Sandoval - 通讯作者:
Arturo Reyes-Sandoval
Safety and immunogenicity of the heterologous prime-boost Ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN<sup>®</sup> FILO in healthy UK adults
- DOI:
10.1016/j.jinf.2015.09.031 - 发表时间:
2015-12-01 - 期刊:
- 影响因子:
- 作者:
Tommy Rampling;Katie Ewer;Georgina Bowyer;Danny Wright;Navin Venkatraman;Ruth Payne;Alfredo Nicosia;Nancy Sullivan;Barney Graham;Andrew Pollard;Simon Draper;Ripley Ballou;Alison Lawrie;Sarah Gilbert;Adrian Hill - 通讯作者:
Adrian Hill
Evaluation of simian adenoviral vector AdCh63 expressing MSP-1 as a candidate blood-stage malaria vaccine
- DOI:
10.1016/j.jinf.2009.10.008 - 发表时间:
2009-12-01 - 期刊:
- 影响因子:
- 作者:
Anna Goodman;Sarah Gilbert;Stefano Colloca;Matthew Dicks;Adrian Hill;Simon Draper - 通讯作者:
Simon Draper
Clinical Evaluation Of New Viral Vectored Vaccines Targeting The Plasmodium Falciparum Blood-Stage Antigens; Msp1 And Ama1
- DOI:
10.1016/j.jinf.2011.04.226 - 发表时间:
2011-12-01 - 期刊:
- 影响因子:
- 作者:
Susanne Sheehy;Christopher Duncan;Nicholas Anagnostou;Sean Elias;Fenella Halstead;Katharine Collins;Katie Ewer;Nick Edwards;Alexander Douglas;Katherine Gantlett;Alison Lawrie;Eleanor Berrie;Sarah Moyles;Carole Long;Robert Sinden;Andrew Blagborough;Jittawadee Murphy;Alfredo Nicosia;Adrian Hill;Simon Draper - 通讯作者:
Simon Draper
Simon Draper的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Simon Draper', 18)}}的其他基金
Carterra LSA for the University of Oxford - Enabling High-Throughput SPR and Antibody Characterisation
牛津大学的 Carterra LSA - 实现高通量 SPR 和抗体表征
- 批准号:
MR/X012085/1 - 财政年份:2022
- 资助金额:
$ 140.75万 - 项目类别:
Research Grant
MICA: Large-Scale Vaccine Fill and Phase I Clinical Trial of the RH5.1/Matrix-M Vaccine against Blood-Stage Plasmodium falciparum Malaria
MICA:针对血期恶性疟原虫疟疾的 RH5.1/Matrix-M 疫苗的大规模疫苗填充和 I 期临床试验
- 批准号:
MR/V038427/1 - 财政年份:2021
- 资助金额:
$ 140.75万 - 项目类别:
Research Grant
A. Olotu, Ifakara Health Institute - Immune responses in malaria-exposed children immunised with a new generation blood-stage malaria vaccine.
A. Olotu,伊法卡拉健康研究所 - 接种新一代血期疟疾疫苗的疟疾暴露儿童的免疫反应。
- 批准号:
MR/P020593/1 - 财政年份:2017
- 资助金额:
$ 140.75万 - 项目类别:
Research Grant
MICA: Development and GMP manufacture of a PfRH5 protein vaccine to induce strain-transcending immunity against blood-stage Plasmodium falciparum.
MICA:开发和 GMP 生产 PfRH5 蛋白疫苗,以诱导针对血液阶段恶性疟原虫的菌株超越免疫力。
- 批准号:
MR/K025554/1 - 财政年份:2013
- 资助金额:
$ 140.75万 - 项目类别:
Research Grant
Developmental Clinical Studies - Clinical evaluation of an AdCh63-MVA PvDBP_RII vaccine for blood-stage Plasmodium vivax
发育性临床研究 - AdCh63-MVA PvDBP_RII 血液期疟原虫疫苗的临床评估
- 批准号:
G1100086/1 - 财政年份:2011
- 资助金额:
$ 140.75万 - 项目类别:
Research Grant
相似海外基金
Evaluation of immunological function of hTERT-specific transgenic T-cell receptor T cells for cancer immunotherapy
hTERT特异性转基因T细胞受体T细胞用于癌症免疫治疗的免疫功能评价
- 批准号:
20K22804 - 财政年份:2020
- 资助金额:
$ 140.75万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Evaluation of safety, tolerability and immunological responses to Lactobacillus johnsonii N6.2 supplementation in adults with Diabetes type 1
成人 1 型糖尿病患者补充约氏乳杆菌 N6.2 的安全性、耐受性和免疫反应评估
- 批准号:
10004045 - 财政年份:2019
- 资助金额:
$ 140.75万 - 项目类别:
Evaluation of safety, tolerability and immunological responses to Lactobacillus johnsonii N6.2 supplementation in adults with Diabetes type 1
成人 1 型糖尿病患者补充约氏乳杆菌 N6.2 的安全性、耐受性和免疫反应评估
- 批准号:
10217121 - 财政年份:2019
- 资助金额:
$ 140.75万 - 项目类别:
Evaluation of safety, tolerability and immunological responses to Lactobacillus johnsonii N6.2 supplementation in adults with Diabetes type 1
成人 1 型糖尿病患者补充约氏乳杆菌 N6.2 的安全性、耐受性和免疫反应评估
- 批准号:
10427311 - 财政年份:2019
- 资助金额:
$ 140.75万 - 项目类别:
The evaluation of mineral oil immunological effects included in diesel fuel and of mechanism of the immunological effect
柴油中矿物油免疫作用的评价及其免疫作用机制
- 批准号:
20590607 - 财政年份:2008
- 资助金额:
$ 140.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Immunological evaluation and prediction of the effectiveness of interferon therapy for the Japanese multiple sclerosis patients
日本多发性硬化症患者干扰素治疗效果的免疫学评价及预测
- 批准号:
19790622 - 财政年份:2007
- 资助金额:
$ 140.75万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
SAFETY AND IMMUNOLOGICAL EVALUATION OF NY-ESO-1 PLASMID DNA (PPJV7611) CANCER
NY-ESO-1 质粒 DNA (PPJV7611) 癌症的安全性和免疫学评估
- 批准号:
7604193 - 财政年份:2007
- 资助金额:
$ 140.75万 - 项目类别:
SAFETY AND IMMUNOLOGICAL EVALUATION OF NY-ESO-1 PLASMID DNA (PPJV7611) CANCER
NY-ESO-1 质粒 DNA (PPJV7611) 癌症的安全性和免疫学评估
- 批准号:
7378400 - 财政年份:2006
- 资助金额:
$ 140.75万 - 项目类别:
SAFETY AND IMMUNOLOGICAL EVALUATION OF NY-ESO-1 PLASMID DNA (PPJV7611) CANCER
NY-ESO-1 质粒 DNA (PPJV7611) 癌症的安全性和免疫学评估
- 批准号:
7200401 - 财政年份:2005
- 资助金额:
$ 140.75万 - 项目类别:
Study of prognostic prediction in stage III and IV gastric carcinoma by immunological evaluation
免疫学评估对III、IV期胃癌预后的预测研究
- 批准号:
16591286 - 财政年份:2004
- 资助金额:
$ 140.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




